|
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size. |
|
|
Stock and Other Ownership Interests - Turning Point Therapeutics |
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Merck; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Takeda; TP Therapeutics |
Speakers' Bureau - AstraZeneca; Genentech; Takeda |
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Ignyta (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst) |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health |
|
Margaret Elizabeth McCusker |
Employment - Flatiron Health; Roche |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health; Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Roche |